Showing 1241-1250 of 2819 results for "".
Headache Horizons: Reversible Cerebral Vasoconstriction Syndrome: Presentation, Diagnosis, and Treatment of a Complex Neurovascular Disorder
https://practicalneurology.com/diseases-diagnoses/headache-pain/headache-horizons-reversible-cerebral-vasoconstriction-syndrome-presentation-diagnosis-and-treatment-of-a-complex-neurovascular-disorder/32145/Early diagnosis of and intervention for reversible cerebral vasoconstriction syndrome produce a more favorable outcome, limiting potentially disabling or fatal sequelae.Inpatient Headache Treatment
https://practicalneurology.com/diseases-diagnoses/headache-pain/inpatient-headache-treatment/31903/A multidisciplinary approach with scheduled and as needed medications and nonpharmacologic treatments provides best outcomes of inpatient headache care.MS Minute: Update on BTK Inhibitors for Multiple Sclerosis—A New Treatment That Brings New Hope
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/update-on-btk-inhibitors-for-multiple-sclerosis-a-new-treatment-that-brings-new-hope/40007/BTK inhibitors are the first class of medications to slow disability progression in secondary progressive multiple sclerosis without clinical relapses.Managing Symptoms of Depression, Apathy, Psychosis, and Agitation in People Living with Alzheimer Disease
https://practicalneurology.com/archives/aug-2025-issue/managing-symptoms-of-depression-apathy-psychosis-and-agitation-in-people-living-with-alzheimer-disease/36689/Optimal treatment of neuropsychiatric symptoms in Alzheimer disease necessitates early identification, rigorous clinical differentiation, and the development of individualized therapeutic approaches.Parkinson’s Disease Treatment Update
https://practicalneurology.com/diseases-diagnoses/movement-disorders/parkinsons-disease-treatment-update/31571/New formulations for motor symptoms and new treatments for nonmotor symptoms provide more options.Frontotemporal Dementias
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/frontotemporal-dementias/31537/Careful clinical, neuropsychologic, and imaging investigations make differential diagnosis of variants possible.- Barancik Prize Awarded to Sergio E. Baranzini, PhD at ACTRIMS 2024https://practicalneurology.com/news/barancik-prize-awarded-to-sergio-e-baranzini-phd-at-actrims-2024/2470413/This year, the National Multiple Sclerosis Society has awarded Sergio E. Baranzini, PhD the prestigious Barancik Prize for Innovation in Multiple Sclerosis (MS) Research. Professor Baranzini is a geneticist, neuroimmunologist, and data scientist at the University of California, San Francisco (UCS
- Award Recipients Recognized at 2025 International MDS Conferencehttps://practicalneurology.com/news/award-recipients-recognized-at-the-2025-international-congress-of-parkinsons-disease-and-movement-disorders/2483939/The International Parkinson’s Disease and Movement Disorders Society (MDS) has recognized recipients of the 2025 MDS Awards. The awards honor professionals in the field who are elevating care for movement disorders through their contributions to research, scholarship, and clinical work. The award
- Remembering Ronald DeVere, MD, FAANhttps://practicalneurology.com/news/remembering-ronald-devere-md-faan/2470936/Ronald DeVere, MD, FAAN, Practical Neurology Editorial Advisory Board member and former Editor of the Dementia Insights column, passed away on May 8, 2024, at age 80. Dr. DeVere served as the Director of the Taste & Smell Disorders Clinic and the Alzheimer Disease & Memory Disorder
- New Insights into ARIA-E Risk from Donanemab Studieshttps://practicalneurology.com/news/new-insights-into-aria-e-risk-from-donanemab-studies/2470464/In an effort to understand more about amyloid-related imaging abnormalities (ARIA) associated with anti-amyloid therapy, researchers analyzed pooled data from 3 studies involving donanemab (Eli Lilly and Company, Indianapolis, IN) therapy for individuals with early Alzheimer disease (AD):